IRIDEX (IRIX) Stock Price, News & Analysis

Company Overview

IRIDEX Corporation develops and markets ophthalmic laser systems and related delivery devices used by eye-care professionals. Its technologies are designed primarily to treat glaucoma and retinal diseases, including conditions that can lead to vision loss.

The company’s product portfolio includes laser systems, probes and treatment delivery devices that support procedures such as MicroPulse cyclophotocoagulation and retinal photocoagulation. Its Cyclo G6 platform is used in glaucoma treatments, while its retinal laser products are intended for procedures involving diseases of the retina.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves ophthalmologists, hospitals, ambulatory surgery centers and other eye-care providers. The company markets its products in the United States and internationally through direct sales and distribution relationships.

Key Stats

• Today's Range: $0.62 to $0.65
• 50-Day Range: $0.61 to $0.93
• 52-Week Range: $0.61 to $1.65
• Volume: 27,842 shs
• Average Volume: 49,903 shs
• Market Capitalization: $10.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

IRIDEX Stock Analysis - MarketRank™

IRIDEX scored higher than 37% of companies evaluated by MarketBeat, and ranked 717th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

IRIDEX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

IRIDEX has a consensus price target of $3.00, representing about 380.0% upside from its current price of $0.63.

Amount of Analyst Coverage

IRIDEX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IRIDEX is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IRIDEX is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.00% of the float of IRIDEX has been sold short.

Short Interest Ratio / Days to Cover

IRIDEX has a short interest ratio ("days to cover") of 2.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IRIDEX has recently increased by 8.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IRIDEX does not currently pay a dividend.

Dividend Growth

IRIDEX does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.46

News Sentiment

IRIDEX has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for IRIDEX this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IRIDEX insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.60% of the stock of IRIDEX is held by insiders.

Percentage Held by Institutions

20.10% of the stock of IRIDEX is held by institutions.

Company Calendar

• Last Earnings: 8/18/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:IRIX
• CIK: 1006045
• Web: www.iridex.com
• Phone: (650) 940-4700
• Fax: 650-940-4710
• Employees: 108
• Year Founded: 1989

Price Target and Rating

• Average Price Target for IRIDEX: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +380.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.44 million
• Net Margins: -6.88%
• Pretax Margin: -6.58%
• Return on Equity: N/A
• Return on Assets: -12.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.82
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $51.57 million
• Price / Sales: 0.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.06) per share
• Price / Book: -10.42

Miscellaneous

• Outstanding Shares: 17,565,000
• Free Float: 16,054,000
• Market Cap: $10.98 million
• Optionable: Optionable
• Beta: 0.62